Kamada Ltd. Shareholders Approve Key Resolutions at Annual Meeting
I'm PortAI, I can summarize articles.
Kamada Ltd. held its Annual General Meeting on December 10, 2025, where shareholders approved key resolutions, including re-election of directors, CEO options, amended compensation policy, and amendments for director indemnification. Kost Forer Gabbay & Kasierer was re-appointed as auditors. These decisions aim to enhance corporate governance and operations, potentially benefiting market position and stakeholder relations. Kamada operates in the biopharmaceutical industry, specializing in plasma-derived protein therapeutics, with a current market cap of ILs1.26B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments